XML 95 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1

Other operating income	12 Months Ended
	Dec. 31, 2024
Analysis of income and expense [abstract]
Other operating income	Other operating income Other operating income totaled €1,089 million in 2024, versus €979 million in 2023 and €1,814 million in 2022. Other operating income includes (i) gains from asset divestments, amounting to €539 million in 2024 (versus €484 million in 2023 and €481 million in 2022); and (ii) income from Sanofi’s pharmaceutical partners, amounting to €221 million in 2024 (including €166 million from Regeneron, see Note D.26. below and Note C.1.), compared with €285 million in 2023 (including €227 million from Regeneron), and €1,179 million in 2022. Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

X

- References

No definition available.

+ Details

Name:	ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of other operating income. [Refer: Other operating income (expense)]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration